VBC and Sinopharm Sign Landmark MOU at Africa Health ExCon to Boost Egypt’s Vaccine Production
In a major step towards strengthening Egypt’s vaccine manufacturing capabilities, Vaccines and Biotechnology City (VBC), a member of the Egyptian Vaccine Manufacturers Alliance (EVMA), has signed a Memorandum of Understanding (MOU) with China National Biotec Group Company Limited (CNBG) – Sinopharm. The signing took place on June 25, 2025, during the EVMA Day event at Africa Health EXcon, with the EVMA operating under the auspices of the Egyptian Authority for Unified Procurement (UPA).
The MOU outlines a strategic partnership focused on the technology transfer and local manufacturing of several human vaccines in Egypt. This collaboration is set to significantly contribute to the national strategy for vaccine localization and enhance the country’s self-sufficiency in crucial health products.
The signing ceremony was a high-profile event, attended by key figures from both sides. His Excellency Dr. Hesham Stait, President of the Egyptian Authority for Unified Procurement (UPA), was present to witness the milestone. Representing VBC were Major General Dr. Mohsen Azouz, VBC Chairman, and Dr. Esraa Refaat, Technical Assistant to the Chairman and CEO. From CNBG – Sinopharm, the delegation included Ms. LI Xiuling, Vice President; Ms. XU Tianfang, Country Business Manager, Global Business Unit; and Mr. XU Ye, Deputy Manager, International Cooperation Dept. of Beijing Institute Biological Products Co., Ltd., a subsidiary of CNBG.
This partnership is a testament to the growing global recognition of Egypt’s potential as a regional hub for vaccine production and supply. The technology transfer from Sinopharm will enable VBC to leverage advanced expertise and accelerate the local manufacturing process, ultimately ensuring a more secure and accessible supply of vaccines for the Egyptian population and beyond.